

Stereotaxis Reports 2024 Third Quarter Financial Results

November 11, 2024

ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- <u>Stereotaxis</u> (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2024.

"The past quarter was marked by solid commercial execution, continued broad-based technological progress, successful operational integration of APT, and maintained financial discipline," said David Fischel, Chairman and CEO. "We are making broad, methodical progress in establishing the healthy foundations for a preeminent robotic surgery company."

"Revenue growth in the third quarter was driven by continued demand for Genesis with partial revenue recognition of three robotic systems. We received orders for two Genesis systems during the third quarter and expect to receive the first GenesisX order in the near future. A robust system pipeline along with existing system backlog of over \$15 million supports continued revenue growth."

"We are driving broad-based progress across the late stages of a comprehensive innovation strategy. European CE Mark approval of the MAGiC ablation catheter is expected in the near future. Engagement with the FDA on the MAGiC PMA submission has continued to advance well. We attained CE Mark for the GenesisX robotic system in the third quarter and the FDA provided its first round of questions on the US submission. Following our recent acquisition of APT, we completed manufacturing of hundreds of catheters needed for formal regulatory testing of the first ever robotic high-density mapping catheter and vascular guidance catheter, both of which are expected to be submitted for regulatory approvals next quarter. A recent audit by the Chinese NMPA regulatory body was completed successfully, portending well for near term approvals in China. This broad-based progress on a new foundational product ecosystem is transformational clinically, commercially and strategically as we make robotics increasingly impactful and accessible across endovascular surgery."

"The acquisition of APT in the third quarter is already demonstrating commercial and strategic value. I want to thank and highlight both teams for the significant efforts and accomplishments in integrating operations successfully. The unique expertise of APT is highly complementary and additive to Stereotaxis' strategy as we increasingly focus on a broad family of robotically-steered endovascular devices."

"We remain cognizant of the importance of maintaining financial strength and discipline. Increased system revenue late in the third quarter led to significant associated cash receipts, providing us a solid balance sheet with over \$13 million in cash and no debt at the end of October."

2024 Third Quarter Financial Results

Revenue for the third quarter of 2024 totaled \$9.2 million, an 18% year-over-year increase compared to \$7.8 million in the prior year third quarter. System revenue for the quarter was \$4.4 million and recurring revenue was \$4.8 million, compared to \$3.5 million and \$4.3 million in the prior year third quarter, respectively. System revenue growth reflects revenue recognition on the partial delivery of three Genesis systems. Recurring revenue growth benefited from a partial quarter contribution from the previously announced acquisition of Access Point Technologies.

Gross margin for the third quarter of 2024 was 45% of revenue. Gross margin was impacted by the higher proportion of system revenue and by acquisition-related accounting that temporarily reduces disposable margin. Operating expenses in the third quarter of \$10.4 million include \$2.5 million in non-cash stock compensation expense and a \$0.7 million non-cash, mark-to-market adjustment for acquisition related contingent earnout consideration. Excluding these non-cash charges, adjusted operating expenses in the quarter were \$7.2 million, compared to \$7.1 million in the prior year third quarter. Operating expenses in the third quarter include the partial quarter operating expenses of Access Point Technologies.

Operating loss and net loss in the third quarter were (\$6.3) million and (\$6.2) million, respectively, compared with (\$5.6) million and (\$5.4) million in the prior year third quarter. Adjusted operating loss and adjusted net loss for the quarter, excluding non-cash stock compensation expense and the mark-to-market adjustment, were (\$3.1) million and (\$3.0) million, respectively, compared with (\$3.0) million and (\$2.8) million in the previous year. Negative free cash flow for the third quarter was (\$4.2) million.

Cash Balance and Liquidity

At September 30, 2024, Stereotaxis had cash and cash equivalents, including restricted cash, of \$11.0 million and no debt. Significant cash receipts in October increased Stereotaxis' balance of cash and cash equivalents, including restricted cash, to \$13.3 million at the end of October.

Forward Looking Expectations

Stereotaxis reiterates its expectation for full year revenue to be approximately equal to the previous year, and expects continued year-over-year revenue growth in both system and recurring revenue in the upcoming quarters.

Stereotaxis anticipates ending the year with approximately \$12 million cash and no debt. It expects this balance sheet to allow it to advance its transformative product ecosystem to market, fund its commercialization, and reach profitability without the need for additional financing.

Conference Call and Webcast

Stereotaxis will host a conference call and webcast today, November 11, 2024, at 4:30 p.m. Eastern Time. To access the conference call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 7792742. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at www.Stereotaxis.com.

About Stereotaxis

Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations

help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Company Contacts:

David L. Fischel
Chairman and Chief Executive Officer

Kimberly R. Peery Chief Financial Officer

Basic

314-678-6100 Investors@Stereotaxis.com

STEREOTAXIS, INC. STATEMENTS OF OPERATIONS (Unaudited)

(in thousands, except share and per share amounts)	Three Months Ended September 30,				Nine Months Ended September 30,			
		2024		2023		2024		2023
Revenue:								
Systems	\$	4,391	\$	3,539	\$	7,243	\$	8,673
Disposables, service and accessories		4,805		4,260		13,335		13,533
Total revenue		9,196		7,799		20,578		22,206
Cost of revenue:								
Systems		3,673		2,909		5,760		7,309
Disposables, service and accessories		1,424		831		3,440		2,775
Total cost of revenue		5,097		3,740		9,200		10,084
Gross margin		4,099		4,059		11,378		12,122
Operating expenses:								
Research and development		2,454		2,668		6,970		8,061
Sales and marketing		3,152		3,097		9,456		9,585
General and administrative		4,838		3,933		12,064		11,011
Total operating expenses		10,444		9,698		28,490		28,657
Operating loss		(6,345)		(5,639)		(17,112)		(16,535
Other income		5		-		2		27
Interest income, net		150		270		580		835
Net loss	\$	(6,190)	\$	(5,369)	\$	(16,530)	\$	(15,673
Cumulative dividend on convertible preferred stock		(328)		(338)		(984)		(1,004
Net loss attributable to common stockholders	\$	(6,518)	\$	(5,707)	\$	(17,514)	\$	(16,677
Net loss per share attributed to common stockholders:								
Basic	\$	(0.08)	\$	(0.07)	\$	(0.21)	\$	(0.21
Diluted	\$	(0.08)	\$	(0.07)	\$	(0.21)	\$	(0.21
Weighted average number of common shares and equivalents:								
Desile		05 004 700		00 400 074		04 000 504		00 000 040

85,824,789

82,468,971

84,629,531

80,028,243

Diluted 85,824,789 82,468,971 84,629,531 80,028,243

STEREOTAXIS, INC. BALANCE SHEETS

Name	(in thousands, except share amounts)		September 30, 2024		December 31, 2023	
Current assets: \$ 1,063 \$ 19,818 Cash and cash equivalents 350 52 Restricted cash - current 350 52 Accounts receivable, net of allowance of \$661 and \$672 at 2024 and 2023, respectively 7,921 3,822 Inventories, net 8,812 3,326 Prepaid expenses and other current assets 8,812 3,333 Total current assets 8,813 4,343 Property and equipment, net 3,733 3,336 Goodwill 4,449 4,449 Intangible assets 5,618 4,882 Restricted cash 1,6 2,2 Restricted cash 5,618 4,882 Prepaid and other non-current assets 5,618 4,882 Italialities and stockholders' equity 5,518 4,882 Italialities and stockholders' equity 3,37 2,97 Accounts payable 6,603 3,37 2,97 Accounts payable 6,603 3,37 2,97 Current portion of operating lease liabilities 2,02 6,55 Cur	(
Cash and cash equivalents \$ 10,663 \$ 19,816 Restricted cash - current 350 522 Accounts receivable, net of allowance of \$661 and \$672 at 2024 and 2023, respectively 7,921 3,222 Inventories, net 869 677 Total current assets 28,812 33,261 Total current assets 28,812 33,361 Property and equipment, net 3,733 3,300 Goodwill 4,444 1,444 Intangible assets 5,618 4,882 Restricted cash 5,618 4,982 Operating lease right-of-use assets 5,618 4,982 Prepaid and other non-current assets 5,118 4,982 Prepaid and other non-current assets 116 13 Total assets 5,033 5,033 4,900 Labilities and stockholders' equity 5,032 6,6403 3,190 Accounts payable 6,6403 5,192 6,640 3,376 2,977 Accrued liabilities 5,032 6,528 4,22 2,272 1,242 1,	Assets	·	•			
Restricted cash - current 350 525 Accounts receivable, net of allowance of \$661 and \$672 at 2024 and 2023, respectively 7,921 3,822 Inventories, net 9,000 8,424 Prepaid expenses and other current assets 28,9 67 Total current assets 28,812 33,26 Property and equipment, net 3,733 3,300 Goodwill 4,494 1 Intangible assets 8,162 2 Restricted cash - 215 Operating lease right-of-use assets 5,618 4,982 Prepaid and other non-current assets 116 1,33 Total assets \$ 5,033 \$ 1,900 Liabilities and stockholders' equity \$ 6,403 \$ 3,19 Current point payable \$ 6,403 \$ 3,19 Accounts payable \$ 6,403 \$ 3,29 Deferred revenue 5,02 42 Current point consideration 5,52 42 Current point gene tronsideration 6,25 42 Long-term deferred revenue 5,53	Current assets:					
Accounts receivable, net of allowance of \$661 and \$672 at 2024 and 2023, respectively Inventories, net 7,921 3,822 Inventories, net 869 6,77 Total current assets 28,812 3,236 Froppid expenses and other current assets 28,812 3,236 Goodwill 4,444 4,444 Intangible assets 8,162 21 Restricted cash 5,618 4,882 Operating lease right-of-use assets 5,618 4,882 Operating lease right-of-use assets 116 13 Total assets 50,935 \$ 41,909 User It labilities 3,076 2,972 Accounts payable \$ 6,403 \$ 1,992 Accounts payable \$ 6,403 \$ 1,992 Accounts payable \$ 6,605 2,972 Current contingent consideration 5,298 42 Current contingent consideration 5,298 42 Total current labilities 5,50 42 Total current labilities 5,50 4 Coperating lease liabilities 5,5	Cash and cash equivalents	\$	10,663	\$	19,818	
Prepaid expenses and other current assets 9,000 8,22 Prepaid expenses and other current assets 28,812 33,261 Property and equipment, net 3,733 33,300 Property and equipment, net 4,494 4,494 Restricted cash 5,616 4,805 Prepaid and other non-current assets 5,616 4,805 Prepaid and other non-current assets 1,100 1,000 Prepaid and other non-current assets 1,100 Prepaid and stockholders' equity Current liabilities and stockholders' equity Current liabilities 3,376 2,977 Peter devenue 3,076 3,190 Accrued liabilities 3,376 2,977 Deferred revenue 5,092 6,655 Current contingent consideration 5,298 4,297 Current portion of operating lease liabilities 5,298 4,297 Current general deferred revenue 5,092 6,655 Current contingent consideration 5,298 5,298 Current portion of operating lease liabilities 5,583 5,065 Current deferred revenue 5,093 5,095 Current portion of operating lease liabilities 5,583 5,065 Current deferred revenue 5,094 5,595 5,40 Current portion gent consideration 5,583 5,065 Current portion of operating lease liabilities 5,583 5,065 Current portion of operating lease liabilities 5,593 5,065 Current portion of operating lease liabilities 5,593	Restricted cash - current		350		525	
Prepaid expenses and other current assets 869 676 Total current assets 28,812 33,26 Property and equipment, net 37,33 33,06 Goodwill 4,494 14,94 Intangible assets 8,162 215 Restricted cash 5,618 4,985 Operating lease right-of-use assets 5,118 4,985 Prepaid and other non-current assets 116 13 Total assets 5,033 \$ 1,005 Liabilities and stockholders' equity \$ 6,003 \$ 1,105 Lize true It liabilities \$ 6,003 \$ 3,19 Accounts payable \$ 6,003 \$ 3,19 Accounts payable \$ 6,003 \$ 3,19 Current contingent consideration 5,002 4,29 Current portion of operating lease liabilities 5,52 42 Total current ideferred revenue 20,721 13,24 Cutered contingent consideration 5,53 5,60 Cutered mobilities 5,53 5,60 Collecting lease liabilities 5,53 4<	Accounts receivable, net of allowance of \$661 and \$672 at 2024 and 2023, respectively		7,921		3,822	
Total current assets 28,812 33,266 Property and equipment, net 3,733 3,300 Goodwill 4,494 1 Intangible assets 8,162 215 Restricted cash 5,618 4,882 Operating lease right-of-use assets 5,618 4,882 Prepaid and other non-current assets 116 133 Total assets 50,935 \$ 14,905 Liabilities and stockholders' equity \$ 5,035 \$ 14,905 Current liabilities \$ 6,403 \$ 3,19 Accrued liabilities \$ 3,376 \$ 2,972 Deferred revenue \$ 6,92 6,65 Current portin of operating lease liabilities \$ 5,29 42,66 Total current liabilities \$ 20,721 13,24 Long-term deferred revenue \$ 20,721 13,24 Long-term contingent consideration \$ 5,593 \$ 6,60 Operating lease liabilities \$ 5,593 \$ 6,60 Operating lease liabilities \$ 5,593 \$ 6,60 Corrent contingent consideration \$ 5,593 <td>Inventories, net</td> <td></td> <td>9,009</td> <td></td> <td>8,426</td>	Inventories, net		9,009		8,426	
Property and equipment, net 3,733 3,300 Goodwill 4,494 4,494 Intangible assets 8,162 215 Restricted cash 5,618 4,982 Prepaid and other non-current assets 5,618 4,982 Prepaid and other non-current assets 50,935 \$ 14,905 Total assets 50,935 \$ 14,905 Liabilities and stockholders' equity 50,935 \$ 14,905 Current liabilities 3,376 2,977 Accruel place limities 3,376 2,977 Accruel liabilities 5,092 6,655 Deferred revenue 5,092 6,655 Current portion of operating lease liabilities 20,721 13,24 Long-term deferred revenue 2,102 1,635 Corge-term deferred revenue 5,298 5,66 Corge-term contingent consideration 6,251 6,655 Operating lease liabilities 3,471 6,655 Cong-term contingent consideration 5,583 5,66 Operating lease liabilities 5,583	Prepaid expenses and other current assets		869		676	
Goodwill 4,494 Intangible assets 8,162 Restricted cash - 215 Operating lease right-of-use assets 5,618 4,982 Prepaid and other non-current assets 116 133 Total assets 50,935 41,905 Liabilities and stockholders' equity 8 6,403 \$ 1,905 Current liabilities 3,376 2,977 Accounts payable \$ 6,403 \$ 1,907 Accrued liabilities 3,376 2,977 Deferred revenue 5,092 6,655 Current portion of operating lease liabilities 552 425 Total current portion of operating lease liabilities 552 425 Long-term contingent consideration 20,721 13,247 Long-term deferred revenue 5,052 552 Long-term contingent consideration 5,53 5,665 Coperating lease liabilities 5,53 5,066 Operating lease liabilities 5,53 4,25 Conycertible preferred stock. 5,53 4,25 <	Total current assets		28,812		33,267	
Intangible assets 8,162 Restricted cash - 215 Operating lease right-of-use assets 5,618 4,986 Prepaid and other non-current assets 1116 133 Total assets 50,935 41,905 Liabilities and stockholders' equity 50,935 41,905 Current liabilities 3,376 2,977 Accounts payable 5,643 5,186 Accrued liabilities 5,092 6,655 Deferred revenue 5,092 6,655 Current contingent consideration 5,298 42 Total current liabilities 20,721 13,24 Total current deferred revenue 2,102 1,633 Long-term deferred revenue 6,251 43 Operating lease liabilities 5,58 5,062 Other liabilities 3,712 1,935 Total current liabilities 5,58 5,062 Other liabilities 3,712 1,633 Total liabilities 5,58 4,53 Total liabilities 5,58 4,53 </td <td>Property and equipment, net</td> <td></td> <td>3,733</td> <td></td> <td>3,304</td>	Property and equipment, net		3,733		3,304	
Restricted cash -	Goodwill		4,494		-	
Operating lease right-of-use assets 5,618 4,986 Prepaid and other non-current assets 116 133 Total assets 5,093 41,900 Liabilities and stockholders' equity 5,093 41,900 Current liabilities 6,403 3,190 Accounts payable 6,403 9,319 Accrued liabilities 3,376 2,972 Deferred revenue 5,092 6,655 Current contingent consideration 5529 422 Condition of operating lease liabilities 20,721 13,244 Long-term deferred revenue 6,251 422 Conjecture contingent consideration 6,251 422 Operating lease liabilities 5,583 5,06 Other liabilities 34,712 19,988 Series A - Convertible preferred stock. 5,583 5,06 Cornwentible preferred stock, Series A, par value \$0,001; 10,000,000 shares authorized, 21,683 and 22,358 shares outstanding at 2024 and 2023, respectively 5,577 Stockholders' equity 85 86 Common stock, par value \$0,001; 300,000,000 shares authorized, 84,71	Intangible assets		8,162		-	
Prepaid and other non-current assets 116 133 Total assets \$ 50,935 \$ 41,905 Liabilities and stockholders' equity \$ 50,935 \$ 41,905 Current liabilities \$ 6,403 \$ 3,190 Accounts payable \$ 6,403 \$ 3,190 Accured liabilities 5,092 6,655 Deferred revenue 5,092 6,655 Current contingent consideration 5,298 420 Current portion of operating lease liabilities 20,721 13,244 Long-term deferred revenue 20,721 13,244 Long-term contingent consideration 6,251 420 Long-term contingent consideration 5,583 5,065 Long-term contingent consideration 5,583 5,065 Operating lease liabilities 3,376 2,2721 13,244 Long-term contingent consideration 5,583 5,065 Operating lease liabilities 3,471 19,985 Total liabilities 5,583 5,065 Conjustic perferred stock. 5,583 5,583	Restricted cash		-		219	
Total assets \$ 50,935 \$ 41,905 Liabilities and stockholders' equity \$ 6,403 \$ 3,190 Current liabilities: \$ 6,403 \$ 3,190 Accounts payable \$ 6,403 \$ 3,190 Accrued liabilities 3,376 2,972 Deferred revenue 5,092 6,655 Current portion of operating lease liabilities 552 425 Total current liabilities 20,721 13,247 Long-term deferred revenue 2,102 1,637 Long-term deferred revenue 6,251 6,251 Long-term contingent consideration 6,251 6,251 Operating lease liabilities 5,583 5,066 Other liabilities 34,712 19,983 Series A - Convertible preferred stock: 34,712 19,983 Series A - Convertible preferred stock, Series A, par value \$0.001; 10,000,000 shares authorized, 21,683 and 22,388 shares outstanding at 2024 and 2023, respectively 5,408 5,577 Stockholders' equity: 5,408 5,577 5,577 Common stock, par value \$0.001; 300,000,000 shares authorized, 84,713,400 and 80,949,697 shares is sued at	Operating lease right-of-use assets		5,618		4,982	
Liabilities and stockholders' equity Current liabilities \$ 6,403 \$ 3,190 Accounts payable \$ 6,403 \$ 3,190 Accounts diabilities 3,376 2,972 Deferred revenue 5,092 6,655 Current contingent consideration 5,298 426 Current pilabilities 20,721 13,247 Long-term deferred revenue 2,102 1,637 Long-term contingent consideration 6,251 Operating lease liabilities 5,583 5,062 Other liabilities 5,583 5,062 Other liabilities 34,712 19,985 Series A - Convertible preferred stock: 5 4 Convertible preferred stock, Series A, par value \$0.001; 10,000,000 shares authorized, 21,683 and 22,358 shares outstanding at 2024 and 2023, respectively 5,408 5,577 Stockholders' equity: Common stock, par value \$0.001; 300,000,000,000 shares authorized, 84,713,400 and 80,949,697 shares issued at 2024 and 2023, respectively 85 8 Accumulated deficit (2006) (2006) (2006) Accumulated deficit (5	Prepaid and other non-current assets		116		137	
Current liabilities: \$ 6,403 \$ 3,190 Accounts payable \$ 6,403 \$ 3,190 Accounted liabilities 3,376 2,972 Deferred revenue 5,092 5,092 Current contingent consideration 5,298 Current portion of operating lease liabilities 20,721 13,247 Long-term deferred revenue 2,102 1,637 Long-term contingent consideration 6,251 0 Operating lease liabilities 5,583 5,062 Other liabilities 5,583 5,062 Other liabilities 34,712 19,983 Total liabilities 34,712 19,983 Series A - Convertible preferred stock: 34,712 19,983 Convertible preferred stock, Series A, par value \$0.001; 10,000,000 shares authorized, 21,683 and 22,358 shares outstanding at 2024 and 2023, respectively 5,408 5,577 Stockholders' equity 5,68 8 Additional paid-in capital 565,146 554,414 Treasury stock, 4,015 shares at 2024 and 2023 6,206 6,206 Accumulated deficit (554,210) (537,680 Total stoc	Total assets	\$	50,935	\$	41,909	
Accounts payable \$ 6,403 \$ 3,190 Accrued liabilities 3,376 2,972 Deferred revenue 5,092 6,657 Current contingent consideration 5,298 2,072 Current portion of operating lease liabilities 20,721 13,247 Long-term deferred revenue 2,072 1,637 Long-term contingent consideration 6,251	Liabilities and stockholders' equity					
Accrued liabilities 3,376 2,977 Deferred revenue 5,092 6,657 Current contingent consideration 5,298 Current portion of operating lease liabilities 552 426 Total current liabilities 20,721 13,247 Long-term deferred revenue 2,102 1,637 Long-term contingent consideration 6,251 Operating lease liabilities 5,583 5,062 Other liabilities 55 43 Total liabilities 34,712 19,983 Series A - Convertible preferred stock: Convertible preferred stock, Series A, par value \$0.001; 10,000,000 shares authorized, 21,683 and 22,358 shares outstanding at 2024 and 2023, respectively 5,408 5,577 Stockholders' equity: Common stock, par value \$0.001; 300,000,000 shares authorized, 84,713,400 and 80,949,697 shares issued at 2024 and 2023, respectively 85 8 Additional paid-in capital 565,146 554,144 554,144 Treasury stock, 4,015 shares at 2024 and 2023 (206) (206) Accumulated deficit (537,680 (554,210) (554,210) Total stockholders' equity <t< td=""><td>Current liabilities:</td><td></td><td></td><td></td><td></td></t<>	Current liabilities:					
Deferred revenue 5,092 6,657 Current contingent consideration 5,298 Current portion of operating lease liabilities 552 426 Total current liabilities 20,721 13,247 Long-term deferred revenue 2,102 1,637 Long-term contingent consideration 6,251 6,251 Operating lease liabilities 5,583 5,062 Other liabilities 5,583 5,062 Total liabilities 34,712 19,985 Series A - Convertible preferred stock: Convertible preferred stock, Series A, par value \$0.001; 10,000,000 shares authorized, 21,683 and 22,358 shares outstanding at 2024 and 2023, respectively 5,408 5,577 Stockholders' equity: Common stock, par value \$0.001; 300,000,000 shares authorized, 84,713,400 and 80,949,697 shares issued at 2024 and 2023, respectively 85 8' Additional paid-in capital 565,146 554,146 Treasury stock, 4,015 shares at 2024 and 2023 (206) (206 Accumulated deficit (554,210) (537,680 Total stockholders' equity 10,815 16,345	Accounts payable	\$	6,403	\$	3,190	
Current contingent consideration 5,298 Current portion of operating lease liabilities 552 428 Total current liabilities 20,721 13,247 Long-term deferred revenue 2,102 1,637 Long-term contingent consideration 6,251 Operating lease liabilities 5,583 5,062 Other liabilities 35 4 Total liabilities 34,712 19,985 Series A - Convertible preferred stock: 22,358 shares outstanding at 2024 and 2023, respectively 5,408 5,577 Stockholders' equity: 5 85 85 Common stock, par value \$0.001; 300,000,000 shares authorized, 84,713,400 and 80,949,697 shares issued at 2024 and 2023, respectively 85 85 Additional paid-in capital 565,146 554,144 71 reasury stock, 4,015 shares at 2024 and 2023 (206) (206) Accumulated deficit (554,210) (537,680 653,680 655,4210 6537,680 Total stockholders' equity 10,815 16,345 16,345 10,815 16,345	Accrued liabilities		3,376		2,972	
Current portion of operating lease liabilities 552 428 Total current liabilities 20,721 13,247 Long-term deferred revenue 2,102 1,637 Long-term contingent consideration 6,251 6,251 Operating lease liabilities 5,583 5,062 Other liabilities 55 4,537 Total liabilities 34,712 19,985 Series A - Convertible preferred stock: Convertible preferred stock, Series A, par value \$0.001; 10,000,000 shares authorized, 21,683 and 22,358 shares outstanding at 2024 and 2023, respectively 5,408 5,577 Stockholders' equity: Common stock, par value \$0.001; 300,000,000 shares authorized, 84,713,400 and 80,949,697 shares issued at 2024 and 2023, respectively 85 8 Additional paid-in capital 565,146 554,146 554,146 Treasury stock, 4,015 shares at 2024 and 2023 (206) (206) Accumulated deficit (554,210) (537,680 Total stockholders' equity 10,815 16,345	Deferred revenue		5,092		6,657	
Total current liabilities 20,721 13,247 Long-term deferred revenue 2,102 1,637 Long-term contingent consideration 6,251 Operating lease liabilities 5,583 5,062 Other liabilities 55 4,72 Total liabilities 34,712 19,985 Series A - Convertible preferred stock: Convertible preferred stock, Series A, par value \$0.001; 10,000,000 shares authorized, 21,683 and 22,358 shares outstanding at 2024 and 2023, respectively 5,408 5,577 Stockholders' equity: Common stock, par value \$0.001; 300,000,000 shares authorized, 84,713,400 and 80,949,697 shares issued at 2024 and 2023, respectively 85 8 Additional paid-in capital 565,146 554,144 554,144 7 Treasury stock, 4,015 shares at 2024 and 2023 (206) (206) (206) Accumulated deficit (554,210) (537,680 10,815 16,345	Current contingent consideration		5,298		-	
Long-term deferred revenue 2,102 1,637 Long-term contingent consideration 6,251 Operating lease liabilities 5,583 5,062 Other liabilities 55 45 Total liabilities 34,712 19,985 Series A - Convertible preferred stock. 2,358 shares outstanding at 2024 and 2023, respectively 5,408 5,577 Stockholders' equity: 2,358 shares outstanding at 2024 and 2023, respectively 5,408 5,577 Stockholders' equity: 2,000 shares authorized, 84,713,400 and 80,949,697 shares issued at 2024 and 2023, respectively 85 86 Additional paid-in capital 565,146 554,148 554,148 Treasury stock, 4,015 shares at 2024 and 2023 (206) (206) Accumulated deficit (554,210) (537,686 Total stockholders' equity 10,815 16,345	Current portion of operating lease liabilities		552		428	
Long-term contingent consideration 6,251 Operating lease liabilities 5,583 5,062 Other liabilities 55 43 Total liabilities 34,712 19,983 Series A - Convertible preferred stock: Convertible preferred stock, Series A, par value \$0.001; 10,000,000 shares authorized, 21,683 and 22,358 shares outstanding at 2024 and 2023, respectively 5,408 5,577 Stockholders' equity: Common stock, par value \$0.001; 300,000,000 shares authorized, 84,713,400 and 80,949,697 shares issued at 2024 and 2023, respectively 85 86 Additional paid-in capital 565,146 554,146 754,146 Treasury stock, 4,015 shares at 2024 and 2023 (206) (206) Accumulated deficit (554,210) (537,686) Total stockholders' equity 10,815 16,345	Total current liabilities		20,721		13,247	
Operating lease liabilities 5,583 5,060 Other liabilities 55 43 Total liabilities 34,712 19,985 Series A - Convertible preferred stock: 20,000 20,0	Long-term deferred revenue		2,102		1,637	
Other liabilities 55 43 Total liabilities 34,712 19,985 Series A - Convertible preferred stock. 25 43 Convertible preferred stock, Series A, par value \$0.001; 10,000,000 shares authorized, 21,683 and 22,358 shares outstanding at 2024 and 2023, respectively 5,408 5,577 Stockholders' equity: Common stock, par value \$0.001; 300,000,000 shares authorized, 84,713,400 and 80,949,697 shares issued at 2024 and 2023, respectively 85 85 Additional paid-in capital 565,146 554,146 554,146 Treasury stock, 4,015 shares at 2024 and 2023 (206) (206) Accumulated deficit (554,210) (537,680 Total stockholders' equity 10,815 16,345	Long-term contingent consideration		6,251		-	
Total liabilities 34,712 19,985 Series A - Convertible preferred stock: Convertible preferred stock, Series A, par value \$0.001; 10,000,000 shares authorized, 21,683 and 22,358 shares outstanding at 2024 and 2023, respectively 5,408 5,577 Stockholders' equity: Common stock, par value \$0.001; 300,000,000 shares authorized, 84,713,400 and 80,949,697 shares issued at 2024 and 2023, respectively 85 8 Additional paid-in capital 565,146 554,144 Treasury stock, 4,015 shares at 2024 and 2023 (206) (206) Accumulated deficit (554,210) (537,680 Total stockholders' equity 10,815 16,343	Operating lease liabilities		5,583		5,062	
Series A - Convertible preferred stock: Convertible preferred stock, Series A, par value \$0.001; 10,000,000 shares authorized, 21,683 and 22,358 shares outstanding at 2024 and 2023, respectively 5,408 5,577 Stockholders' equity: Common stock, par value \$0.001; 300,000,000 shares authorized, 84,713,400 and 80,949,697 shares issued at 2024 and 2023, respectively 85 85 Additional paid-in capital 565,146 554,148 Treasury stock, 4,015 shares at 2024 and 2023 (206) (206) Accumulated deficit (554,210) (537,680 Total stockholders' equity 10,815 16,345	Other liabilities		55		43	
Convertible preferred stock, Series A, par value \$0.001; 10,000,000 shares authorized, 21,683 and 22,358 shares outstanding at 2024 and 2023, respectively 5,408 5,577 Stockholders' equity: Common stock, par value \$0.001; 300,000,000 shares authorized, 84,713,400 and 80,949,697 shares issued at 2024 and 2023, respectively 85 85 Additional paid-in capital 565,146 554,146 Treasury stock, 4,015 shares at 2024 and 2023 (206) (206) Accumulated deficit (554,210) (537,680) Total stockholders' equity 10,815 16,345	Total liabilities		34,712		19,989	
22,358 shares outstanding at 2024 and 2023, respectively 5,408 5,577 Stockholders' equity: Common stock, par value \$0.001; 300,000,000 shares authorized, 84,713,400 and 80,949,697 shares issued at 2024 and 2023, respectively 85 8' Additional paid-in capital 565,146 554,146 Treasury stock, 4,015 shares at 2024 and 2023 (206) (206) Accumulated deficit (554,210) (537,680) Total stockholders' equity 10,815 16,345	Series A - Convertible preferred stock:					
Common stock, par value \$0.001; 300,000,000 shares authorized, 84,713,400 and 80,949,697 shares issued at 2024 and 2023, respectively 85 8' Additional paid-in capital 565,146 554,146 Treasury stock, 4,015 shares at 2024 and 2023 (206) (206) Accumulated deficit (554,210) (537,680 Total stockholders' equity 10,815 16,345			5,408		5,577	
issued at 2024 and 2023, respectively 85 87 Additional paid-in capital 565,146 554,148 Treasury stock, 4,015 shares at 2024 and 2023 (206) (206) Accumulated deficit (554,210) (537,680) Total stockholders' equity 10,815 16,343	Stockholders' equity:					
Additional paid-in capital 565,146 554,148 Treasury stock, 4,015 shares at 2024 and 2023 (206) (206) Accumulated deficit (554,210) (537,680) Total stockholders' equity 10,815 16,343			85		81	
Treasury stock, 4,015 shares at 2024 and 2023 (206) (206) Accumulated deficit (554,210) (537,680) Total stockholders' equity 10,815 16,343					554,148	
Accumulated deficit (554,210) (537,680) Total stockholders' equity 10,815 16,343	·		*		(206)	
Total stockholders' equity 10,815 16,343			` ,		(537,680)	
					16,343	
	Total liabilities and stockholders' equity	\$	50,935	\$	41,909	

